Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent infectious disease and cancer
The company’s proprietary heterologous prime-boost platform comprises Chimp Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), which safely mimic viral infection in human cells and elicit high magnitude, durable, targeted CD8+ and CD4+ T cell responses, to clear foreign pathogens and tumours.
The platform was licenced from the prestigious Jenner Institute for vaccine research at the University of Oxford, which dedicated over 20 years of research to identify and refine the optimal method for CD8+ T cell induction in humans. This platform has generated a robust, largely immunotherapeutic pipeline of eight product candidates, four of which are funded and being developed through partners. Three of these products are in Phases 1 through to 2b, with read-outs in 2020. The remaining five products will enter the clinic in 2020.
Vaccitech is backed by leading investment institutions, including GV (formerly Google Ventures), Sequoia Capital China, Neptune, Korea Investment Partners and Oxford Sciences Innovation.